Atypical antipsychotics are prescribed frequently for the treatment of psychotic, disruptive behaviour, personality, mood and pervasive developmental disorders, irritability in autism and learning difficulties in children and adolescents (Adityanjee et al. 2008; DeHert et al. 2011; Zuddas et al. 2011) . Besides selective serotonin reuptake inhibitors (SSRIs), medications used to treat borderline personality disorders (BPD) may include anticonvulsants, but also atypical antipsychotics (Abraham and Calabrese 2008) such as quetiapine (Adityanjee et al. 2008 ). In the Republic of Croatia, quetiapine is registered for the treatment of psychotic and bipolar disorders in patients over 18. However, in children and adolescents who are refractory to treatment, and who develop various behavioural disorders, primarily with symptoms of BPD, the use of atypical antipsychotics is often regarded as necessary. The aim of this study was to evaluate the effects of 24 weeks of add-on treatment with quetiapine (75-600 mg/day) in patients aged 9-17 years with developing BPD, refractory to previous treatment, who had pronounced symptoms of depression, aggression, irritability and suicidal tendencies.
The open trial included 11 male and 11 female patients 9-17 years old (mean015.4, SD01.71), admitted between 2005 and 2007, with hetero-or auto-aggressive (suicidal tendencies and suicidal thoughts), depressive and irritability symptoms that correspond to symptoms in adult BPD. Since the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) does not recognize a diagnosis of BPD before the age of 18, diagnosis was categorized as developing BPD, according to DSM-IV criteria and Revised Diagnostic Interview for Borderline Patients (DIB-R). Refractoriness to treatment was defined when patients had the Children Global Assessment Scale (C-GAS) scores lower than 51 after a few treatment sessions (2 weeks to a few years) with SSRIs (fluvoxamine, sertraline or fluoxetine). After obtaining patient's assents and parent's consents, patients were treated with quetiapine (average daily dose of 390 mg) as an add-on therapy to various SSRIs. Inclusion criteria include diagnosis of developing BPD, except the age criteria, IQ >90, and no positive therapeutic effect of SSRIs. Exclusion criteria include comorbid depressive, psychotic or eating disorders, and concomitant psychiatric therapy by medication other than SSRIs.
Transient somnolence, dry mouth and fatigue were evident in some patients during the first 2 weeks of the trial but resolved spontaneously; no other clinical side effects were recorded. None of the patients required anticholinergic medications, no discontinuation due to side effects was recorded, and all patients finished 24 weeks of the trial. Hospital monitoring was undertaken in the period of 6-8 weeks, and outpatient monitoring after discharge from the hospital department. The primary efficacy measure was a change from baseline to end point in the modified version of the Overt Aggression Scale Modified (OAS-M), and secondary efficacy measures were the six-item Kutcher Adolescent Depression Scale (KADS-6) and the C-GAS. The study was approved by the Ethics Committee of the Psychiatric Hospital for Children and Youth Zagreb. The results, expressed as means ± standard deviations (SD), were evaluated using repeated measures analysis of variance (ANOVA) and Tukey's test. The level of significance was set to p00.05.
Patients had mean DIB-R scores of 8.91±0.75. Quetiapine (average dose 389.77±153.27 mg/day) treatment for 4-24 weeks significantly increased (p<0.001) the total C-GAS scores and significantly decreased (p<0.001) total KADS-6, total OAS-M scores and scores in OAS-M aggression, irritability and suicidality subscales (Table 1) .
To the best of our knowledge, this is the first study to show that the add-on of quetiapine (average dose of 390 mg/day) to SSRIs induced a significant reduction of the symptoms of aggression, irritability, affective instability, suicidality and depression, and significant improvement in the global level of functioning in young people with developing BPD refractory to previous SSRI treatment. The clinical improvement remained stable over 24 weeks of study.
Our results are in line with the reported improvement of the combination of quetiapine and valproate or quetiapine monotherapy in young people with bipolar disorder (DelBello et al. 2009; Zuddas et al. 2011) , in youth with comorbid paediatric bipolar disorder and disruptive behaviour disorder (Barzman et al. 2006 ) and in aggressive children with conduct disorders (Findling et al. 2007 ). In contrast to our results, showing that quetiapine improved slightly but significantly depressive symptoms, quetiapine did not affect symptoms of depression in adolescents with bipolar depression (DelBello et al. 2009 ). Limitations of the study were that adverse effects were not systematically collected and important metabolic indicators such as weight gain, fasting glucose, lipid levels or prolactin increase were not measured (DeHert et al. 2011 ).
In conclusion, this pilot trial confirmed the clinical impression that 24 weeks of quetiapine treatment, added to standard SSRIs, ameliorated aggressive behaviour, intentional self-injury, chronic anxiety and affective instability, depression, suicidal tendencies and irritability in children and adolescents with developing BPD. However, because of its metabolic adverse effects quetiapine must be used with caution in this patient population, and randomised trials with careful safety monitoring are needed.
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